BENZENO SHARON sold $3.5M of ADPT

BENZENO SHARON (Chief Commercial Ofc Imm Med) sold 165,802 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.13 ($21.00–$21.14, $3.50M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BENZENO SHARON
Published Jun 30, 2026, 11:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company-specific fundamentals or catalysts.

02

Market read

Traders may monitor insider activity, but this specific 10b5-1 sale is unlikely to drive a sustained repricing absent other news.

03

What to watch

Insider sales can be misread; without accompanying changes in guidance, trials, or financing, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-30 after trades dated 2026-06-26 to 2026-06-29

Background

The article is an SEC Form 4 insider transaction report for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

SEC Form 4 shows officer Benzeno Sharon sold 165,802 shares of Adaptive Biotechnologies (ADPT) for about $3.50M under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new operational, regulatory, or financial catalyst.

Market effects

No sector read-through; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction; officer sale disclosed.

  • Benzeno Sharon

    Chief Commercial Officer, Immune Med; reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.